Acumen Pharmaceuticals, Inc.
ABOSDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
2
Next Catalyst
This month
Market Overview
Stock performance and key metrics
2 upcoming, 0 past
sabirnetug Phase 2 Est. Readout
Primary completion for sabirnetug trial (NCT06335173) in Alzheimer Disease
Source1 more catalyst beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
sabirnetug | Phase 2 | Alzheimer Disease | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Acumen Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Acumen Pharmaceuticals, Inc.'s (ABOS) pipeline across Phase 2. Its lead program is sabirnetug (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Acumen Pharmaceuticals, Inc.'s next FDA catalyst?→
Acumen Pharmaceuticals, Inc.'s (ABOS) next tracked catalyst is a Phase 2 expected October 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ABOS biotech catalysts?→
Add ABOS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Acumen Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.